Photo by atikahakhtar from unsplash
Hedgehog pathway inhibitors (HPI) inactivating SMO 1 , have become first line treatment for patients with locally advanced BCC (laBCC). HPI safety and efficacy have been shown in clinical trials2,3 .… Click to show full abstract
Hedgehog pathway inhibitors (HPI) inactivating SMO 1 , have become first line treatment for patients with locally advanced BCC (laBCC). HPI safety and efficacy have been shown in clinical trials2,3 . Nevertheless, common adverse events lead to treatment discontinuation. This article is protected by copyright. All rights reserved.
Keywords:
vismodegib resistant;
discontinuation;
locally advanced;
resistant mutations;
mutations selected
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!